Literature DB >> 1647831

Increase in omega 3 (peripheral type benzodiazepine) binding sites in the rat cortex and striatum after local injection of interleukin-1, tumour necrosis factor-alpha and lipopolysaccharide.

F Bourdiol1, S Toulmond, A Serrano, J Benavides, B Scatton.   

Abstract

The possible involvement of lymphokines in the glial reaction/proliferation that follows brain injury has been investigated by measuring the density of omega 3 (peripheral type benzodiazepine) binding sites associated to glial cells and macrophages after local injection of lymphokines in the rat cerebral cortex and striatum. omega 3 Site densities were measured either by quantitative autoradiography in brain sections or by conventional binding in membrane using [3H]PK 14105 or [3H]PK 11195 as ligands. Intracortical or intrastriatal infusion of interleukin-1 (10 and 20 units) caused a marked increase in the density of omega 3 sites (+83% and +80%, respectively, when compared to saline-infused animals) around the injection site at 7 days postinjection. There was a good spatial correspondence between the autoradiographic distribution of omega 3 sites and the distribution of reactive astrocytes (as assessed by GFAP immunostaining) or acid phosphatase rich cells (phagocytes). Significant increases in omega 3 site densities were also observed in striatal homogenates 1 week after local administration of tumor necrosis factor-alpha (TNF-alpha). The maximal increase (+80%) was observed after the administration of 3 units, higher and lower doses resulting in smaller increases. Intrastriatal injection of E. coli lipopolysaccharide (LPS), a bacterial endotoxin known to stimulate interleukin-1 and TNF-alpha production by microglial cells in culture, also resulted in significant increases in omega 3 site densities in striatal homogenates (maximal increase, +170% 1 week after the injection of 200 ng).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647831     DOI: 10.1016/0006-8993(91)90028-t

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging.

Authors:  Sriram Venneti; Brian J Lopresti; Clayton A Wiley
Journal:  Prog Neurobiol       Date:  2006-12-06       Impact factor: 11.685

Review 2.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

4.  Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration.

Authors:  D G MacGregor; T W Stone
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

5.  Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

Authors:  A Machado; A J Herrera; J L Venero; M Santiago; R M de Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano
Journal:  ISRN Neurol       Date:  2011-04-17

6.  TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.

Authors:  Danielle A Simmons; Michelle L James; Nadia P Belichenko; Sarah Semaan; Christina Condon; Jason Kuan; Adam J Shuhendler; Zheng Miao; Frederick T Chin; Frank M Longo
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.